Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

Inclusion Criteria:

• Participants with moderate-to-severe asthma who completed the treatment period ofthe parent study per protocol

• Participants on background dose with medium-to-high doses of ICS therapy (≥500 µg offluticasone propionate daily or comparable ICS dosage up to a maximum of 2000 µg/dayof fluticasone propionate or clinically comparable) in combination with a second orthird controller (eg, LABA, LTRA, LAMA, methylxanthines), with or without OCS (up toa maximum of 15 mg prednisone or equivalent daily or 30 mg every other day) asmaintained during the parent study in which they participated Note for Japan:participants must be on ≥400 μg of fluticasone propionate daily or equivalent.

• Contraception for male and female participants;

For female participants:

• incapable of becoming pregnant

• not pregnant or breast feeding

• not to donate or cryopreserve eggs for female participants For male participants

• No sperm donation or cryopreserving sperms

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Chronic lung disease other than asthma

• Participants who developed a new medical condition or a change in status of anestablished medical condition or require a new treatment or medication prior toenrollment, which (per Investigator's medical judgment) would adversely affect theparticipation in this study or would require permanent IMP discontinuation

• Current smoker or active vaping of any products and/or marijuana smoking

• Prescription drug or substance abuse, including alcohol, considered significant bythe Investigator

• Any new development with the participant's disease or condition or any significantlaboratory test abnormality during the parent study that, in the opinion of theInvestigator, may present an unreasonable risk for the participant

• Sensitivity to any of the study interventions, or components thereof, or drug orother allergy that, in the opinion of the Investigator, contraindicatesparticipation in the study

• Individuals accommodated in an institution because of regulatory or legal order;prisoners or participants who are legally institutionalized

• Participant not suitable for participation, whatever the reason, as judged by theInvestigator, including medical or clinical conditions, or participants potentiallyat risk of noncompliance to study procedures

• Participants are employees of the investigative site or other individuals directlyinvolved in the conduct of the study, or immediate family members of suchindividuals

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.